Strides Pharma's Stock Soars Following USFDA Approval for Gabapentin Tablets Launch

• Dorian Wakefield
• 22 Mar 2024
• Health & Pharmaceuticals

Strides Pharma Science Ltd. has seen a notable uptick in its shares after obtaining the USFDA's tentative approval for Gabapentin tablets in multiple dosages. This nod is a critical step for the company in its quest to dominate the central nervous system treatments market in the U.S.